How Much Is Enough?

This Wall Street Journal looking link takes a look at the $31.9 Million it claims Johnson $ Johnson's CEO William Weldon claims as his own.

Here's an SEC blurb from the above link.

Bloomberg news brings us the following 5 links arranged here in reverse chronology.

5: Earnings up 9.5% as of Jan 22 2008 [Pfizer forked over Listerine.] Bill, so far as we know; LISTERINE ISN'T KILLING people. Risperdal IS.

4:Job Cuts at J&J due to generic competition to Risperdal Nov. 15 2007 Hmmm. The Risperdal Medusa sprouts new heads?
[paragraph 3]

"J&J needs new businesses because it faces generic competition to Risperdal, the company's biggest drug with $4.2 billion in 2006 sales, and the migraine pill Topamax, with $2 billion, over the next two years. Chief Executive Officer William C. Weldon in July announced a $10 billion stock repurchase and plans to eliminate as many as 4,820 jobs.

``We hope we will be able to identify what is the next $20 billion business opportunity,'' Weldon said today in a telephone interview. ``We have the know-how across our pharmaceutical, biologics, devices, diagnostics and consumer businesses to bring completely new solutions to market.''

3: Ortho Evra birth control patch: Sept. 18 2007 problems for women and J&J

2: J&J to Cut Up to 4% of Jobs, Shut Facilities July 31 2007. This puppy needs a teaser.

"The savings will help J&J weather lost revenue from cheaper generics, said Chief Executive Officer William Weldon. The schizophrenia treatment Risperdal, J&J's biggest drug with $4.2 billion in 2006 sales, and the migraine pill Topamax, with $2 billion in revenue, may lose patent protection in 2008. Weldon also cited slower-than-anticipated sales of the Procrit anemia drug and Cypher stent as reasons for the cutbacks.

``We now have a much clearer picture of how J&J plans to respond to the patent expirations,'' said Sara Michelmore, an analyst with Cowen & Co. in New York, in a telephone interview today. ``The[y] needed to outline their strategy, given those issues and the more recent problems with Cypher and Procrit.''

PATENT EXPIRATIONS? How about the 1,093 RISPERDAL PATIENT EXPIRATIONS?

1: J&J announce $10 Billion share buyback. July 9 2007

"J&J last year bought Pfizer's consumer-health unit for $16.6 billion in cash, adding brands such as Listerine mouth wash, Nicorette smoking-cessation treatments and Sudafed cold, flu and allergy products."

Bill must be feeling pretty blue, with his pittance of $31.9 Million.
Here Bill, This ought to brighten your day. Connecticut's dragging your competitor Eli Lilly into Court, for Their version of Risperdal.

Connecticut Sues Lilly Over Zyprexa. March 12 2008

Thanks, and a hat tip to Furious Seasons for brightening Our day.